FDA rejects Pfizer's weekly growth hormone

The US Food and Drug Administration has given the thumbs-down to Pfizer’s once-weekly growth hormone, somatrogon, following a three-month delay in fall of last year. The firm is prepared to enter a dialog with the agency to move forward.

Photo: Cathal Mcnaughton/Reuters/Ritzau Scanpix

US-based pharmaceutical firm Pfizer has suffered a significant blow on the hunt to have its once-weekly growth hormone, somatrogon, approved for the US market.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs